Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Feb 11, 2022 10:21am
142 Views
Post# 34420010

RE:RE:Uploaded by THTX

RE:RE:Uploaded by THTX TH may indeed have a miracle drug and it also may not quite reach that description. But it certainly seems to be leaning in that direction and the company was clearly happy with the state of affairs in their recent meetings with shareholders. But it still seems to be something of a state secret that cannot be talked about widely as share trading volume and option activity is minimal despite the increasing Soleus holding, the addition of Dr. Rothenberg and the trial likely being near its end, if not already there, among other hints that the TH-1902 project is on the right track. THe objective of us who own the stock is to see the stock price rise in response to facts and optimism about the future.  We can't have all the  facts until they report out results of the phase 1a but they can build optimism among investors, which if done professionally - just as countless of other companies have done and are doing - can really enhance the overall result for everyone involved. Instead, we are getting a lot of silence from TH. MY hope is they are working on a major overhaul of how they do things and will use whatever positive announcement they have about the pahse 1a as a springboard to a much better approach. But until we see it, all we can see is the same old low intensity approach to investors that has generated substandard results in the past and will do so again in the future if nothing actually changes.

palinc2000 wrote: She said'' Miracle Drug ""  


<< Previous
Bullboard Posts
Next >>